NCT06592833
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 12 months later.
See at-risk trials from Icahn School of Medicine at Mount Sinai
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Mar 1, 2028 to Mar 2029 Show 4 more changesShow less
- Eligibility criteria expanded, about 32 words
- Study completion pushed from Mar 1, 2028 to Apr 2029
- Secondary endpoints: details revised at 1 of 1 entry
- Site contact updated
- Minor Primary and study completion dates: Jan 2028 to Mar 1, 2028
- Start date: Feb 12, 2025 to Feb 25, 2025
- Study site revised
- Study title expanded, about 9 words
- Minor Start date changed from estimate of Feb 2025 to Feb 12, 2025v5
- Notable Eligibility criteria shortened, about 11 words
- Primary and study completion dates: Mar 2028 to Jan 2028
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Nov 2024 to Feb 2025
- Primary and study completion dates: Sep 2027 to Mar 2028
- Site details revised
- Notable Start date: Sep 2024 to Nov 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Mystical Experience Questionnaire (MEQ-30) Score
Timeframe: 6 hours post-treatment
Secondary (1)
Montgomery-Åsberg Depression Rating Scale (MADRS) Score
Arms and interventions
Psilocybin + PimavanserinActive comparator
single dose Psilocybin and single dose Pimavanserin
Psilocybin + PlaceboPlacebo comparator
single dose Psilocybin and single dose Placebo
Drugs: Psilocybin, Pimavanserin, Placebo
Sites
1 site in 1 country
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York, United States